Get the Stockscreener App
41.92
1.23%
-0.52
After Hours:
41.92
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Axogen Inc stock is traded at $41.92, with a volume of 1.09M.
It is down -1.23% in the last 24 hours and down -17.42% over the past month.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
See More
Previous Close:
$42.44
Open:
$42.35
24h Volume:
1.09M
Relative Volume:
0.89
Market Cap:
$2.46B
Revenue:
$238.11M
Net Income/Loss:
$-31.45M
P/E Ratio:
-66.18
EPS:
-0.6334
Net Cash Flow:
$7.66M
1W Performance:
-3.23%
1M Performance:
-17.42%
6M Performance:
+26.53%
1Y Performance:
+134.98%
1-Day Range:
$41.74
$43.09
1-Week Range:
$41.74
$44.68
52-Week Range:
$15.27
$52.91
Axogen Inc Stock (AXGN) Company Profile
Name
Axogen Inc
Sector
Industry
Phone
(386) 462-6817
Address
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
41.92 | 2.55B | 238.11M | -31.45M | 7.66M | -0.6334 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Wells Fargo | Overweight |
| Dec-01-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Lake Street | Buy |
| Jul-01-24 | Initiated | Raymond James | Outperform |
| Nov-11-22 | Resumed | Jefferies | Buy |
| May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-12-19 | Initiated | Canaccord Genuity | Buy |
| Mar-02-18 | Reiterated | Lake Street | Buy |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-30-17 | Initiated | Jefferies | Buy |
| Nov-21-17 | Reiterated | Lake Street | Buy |
| Jul-31-17 | Initiated | Leerink Partners | Outperform |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-17 | Initiated | ROTH Capital | Buy |
| Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
| Nov-07-16 | Reiterated | Wedbush | Outperform |
| Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-14-14 | Initiated | Dawson James | Buy |
| Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc Stock (AXGN) Latest News
Raymond James raises AxoGen stock price target on growth outlook By Investing.com - Investing.com Nigeria
AXGN Maintains Outperform Rating by Raymond James -- Price Targe - GuruFocus
Raymond James raises AxoGen stock price target on growth outlook - Investing.com
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
AxoGen (AXGN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
AXGN | Axogen, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overva - GuruFocus
Axogen: Sales Sprint Ahead; Profitability Takes a Breather - Orthopedics This Week
Axogen, Inc.Common Stock (Nasdaq:AXGN) Stock Quote - The Chronicle-Journal
Axogen Stock Price Forecast. Should You Buy AXGN? - StockInvest.us
AxoGen, Inc. (AXGN) Stock Analysis: Healthcare Innovator With A 19% Potential Upside - DirectorsTalk Interviews
Axogen, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AXGN) 2026-07-29 - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Definium Therapeutics (DFTX) - The Globe and Mail
Axogen to acquire BioCircuit Technologies for $200 million - Indian Pharma Post
Lake Street Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Axogen to acquire BioCircuit Technologies - Medical Buyer
Axogen (NASDAQ: AXGN) Plans $200M Acquisition of BioCircuit Technologies Backed by Stock Offering - Kalkine Media
Axogen (NASDAQ: AXGN) Releases Updated Investor Presentation on September 10, 2026 - Kalkine Media
Axogen deepens nerve repair portfolio through $200m BioCircuit takeover - Yahoo Finance
Axogen announces pricing of public offering - medicalbuyer.co.in
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com Australia
Axogen Inc (AXGN) Shares Fall 11.5% -- What GF Score of 64 Tells Investors - GuruFocus
AXGN 424B FilingsAxogen Inc SEC 424B - Stock Titan
Axogen To Acquire BioCircuit Technologies For $200 Million To Add Sutureless Nerve Repair Platform - Pulse 2.0
Why Is Axogen Stock Tumbling Today?Axogen (NASDAQ:AXGN) - Benzinga
Axogen to buy BioCircuit Technologies for $200M - medtechdive.com
Axogen Announces $200 Million Acquisition of BioCircuit Technologies Alongside $42.50 Per Share Stock Offering - Kalkine Media
Axogen to acquire Biocircuit for $200M - BioWorld News
2 Medical-Device Stocks Lighting Up the Options Pits - schaeffersresearch.com
Axogen stock falls as $208.7M offering dilutes shareholders By Investing.com - Investing.com Australia
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com South Africa
Why is Axogen stock sliding today? By Investing.com - Investing.com Australia
Axogen stock falls as $208.7M offering dilutes shareholders - Investing.com India
Axogen Prices $208.7 Million Stock Offering to Fund BioCircuit Acquisition - citybiz
Axogen to Acquire BioCircuit Technologies in $200 Million Nerve Repair Deal - citybiz
Why is Axogen stock sliding today? - investing.com
Axogen acquires BioCircuit Technologies for $200 million - grafa.com
Axogen Announces Pricing Of $208.7 Million Public Offering Of Common Stock - TradingView
AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio - TipRanks
Axogen prices $208.7 million stock offering at $42.50 per share - investing.com
AXGN Looks 171.8% Overvalued on GF Value™ - GuruFocus
Axogen to acquire BioCircuit for $200M, adds nerve repair device - Investing.com Canada
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - manilatimes.net
Axogen Prices $208.7 Million Public Offering of Common Stock to Help Fund BioCircuit Acquisition - Quiver Quantitative
AXGN: Acquisition of a pioneering sutureless nerve repair device is expected to drive growth and innovation - TradingView
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies - GlobeNewswire
Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for approximately $200 million. - marketscreener.com
Understanding the Setup: (AXGN) and Scalable Risk - Stock Traders Daily
Axogen Director Tyndall Joseph A. Disposes of 3,500 Shares at $49.70 Each - Kalkine Media
Axogen (AXGN) Director Joseph Tyndall Sells 3,500 Shares - GuruFocus
Axogen Inc (AXGN) Shares Fall 3.2% -- What GF Score of 64 Tells Investors - GuruFocus
Axogen Inc Stock (AXGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):